Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Sethi S, Haas M, Markowitz GS, D'Agati VD, Rennke HG, J Jennette C, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. J Am Soc Nephrol. 2016;27(5):1278-87.

Hipp JA, Jing X, Zarka MA, Schmitt AC, Siddiqui MT, Wakely P, et al. Cytomorphologic characteristics and differential diagnoses of lymphoepithelial carcinoma of the parotid. J Am Soc Cytopathol. 2016;5(2):93-99.

Pizzi M, Boi M, Bertoni F, Inghirami G. Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. Leukemia. 2016;30(9):1805-15.

Greenblatt MB, Shin DY, Oh H, Lee K-, Zhai B, Gygi SP, et al. MEKK2 mediates an alternative β-catenin pathway that promotes bone formation. Proc Natl Acad Sci U S A. 2016;113(9):E1226-35.

Yin Y, Liu L, Yang C, Lin C, Veith GM, Wang C, et al. Cell Autonomous and Nonautonomous Function of CUL4B in Mouse Spermatogenesis. J Biol Chem. 2016;291(13):6923-35.

Kahlert UD, Cheng M, Koch K, Marchionni L, Fan X, Raabe EH, et al. Alterations in cellular metabolome after pharmacological inhibition of Notch in glioblastoma cells. Int J Cancer. 2016;138(5):1246-55.

Solomon JP, Hansel DE. The Emerging Molecular Landscape of Urothelial Carcinoma. Surg Pathol Clin. 2016;9(3):391-404.

Pal S, Tyler JK. Epigenetics and aging. Sci Adv. 2016;2(7):e1600584.

Geyer JT, Orazi A. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates. Int J Lab Hematol. 2016;38 Suppl 1:12-9.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, et al. Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2016;156(2):405-6.